MedTrace Logo

Intravitreal Aflibercept Injection for Polypoidal Choroidal Vasculopathy With Hemorrhage or Exudation

NCT01871376 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2016-11-23

No results posted yet for this study

Summary

To evaluate the efficacy and safety of intravitreal aflibercept injection in the treatment of PCV

Conditions

  • Polypoidal Choroidal Vasculopathy

Interventions

DRUG

Intravitreal aflibercept injection 2.0mg

Monthly 2.0mg intravitreal aflibercept injection, followed by Q8W dosing with 2.0mg intravitreal aflibercept injection or as often as monthly if needed for 1 year for both treatment naive and prior treatment arms.

Sponsors & Collaborators

Principal Investigators

  • Gregg T. Kokame, MD, MMS · Hawaii Pacific Health

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
25 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-05-31
Primary Completion
2016-09-30
Completion
2016-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01871376 on ClinicalTrials.gov